

73 carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-alanine-asparagine- and carbobenzyloxy-valine-valine-; and

R<sub>2</sub> is a radical selected from the group consisting of -(H)<sub>2</sub>, and -H(t-Butyl).

---

### Remarks

Claims 11, 16, and 17 were objected to as depending upon rejected claims. In conformance with Examiner's objections, claims 11, 16, and 17 have been amended so that each is now an independent claim.

Examiner objected that claim 3 was poorly legible. Per Examiner's request, Claim 3 (once amended) has been reproduced here without further amendment.

#### Rejection under 35 U.S.C. § 102(b):

Claim 1 is rejected as anticipated by Tam. Applicant traverses this rejection. However, Applicant has canceled claim 1 without prejudice and reserves the right to pursue this claim in a continuation application.

#### Rejection under 35 U.S.C. § 103(a):

Claims 10 and 12-15 are rejected as obvious over Wo. Applicant traverses this rejection. However, Applicant has canceled claims 10 and 12-15 without prejudice and reserves the right to pursue these claims in a continuation application.



TSRI 609.1  
SN 09/581,044

Summary:

Applicant has cancelled all rejected claims (claims 1, 10, and 12-15).  
Furthermore, Applicant has amended all claims to which Examiner has objected (11, 16,m and 17), so as to bring these claims into conformance with Examiner's objections.

Applicant requests that the above amendments after final be entered and that a Notice of Allowance be provided with respect to claims 3, 6-9, 11, and 16-22.

Respectfully submitted,

Donald G. Lewis  
Reg. No. 28,636  
The Scripps Research Institute  
10550 N. Torrey Pines Road TPC-8  
San Diego, CA 92037  
January 3, 2003  
(858) 784-2937



## APPENDIX

### VERSION OF SPECIFICATION AND CLAIMS WITH MARKINGS TO SHOW CHANGES MADE


#### In the Claims:

Please amend Claims 11, 16, and 17 as follows:

5

11. (once amended) A protease inhibitor [according to claim 10] represented by the following structure:


10



15

16. (once amended) A protease inhibitor [according to claim 10] represented by the following structure:

20



25

17. (once amended) A protease inhibitor [according to claim 10] represented by the following structure:

